Oncodesign has appointed Karine Lignel as Group Chief Development Officer

Read the pdf

Paris and Dijon (France), October 25, 2021 – 18:00 CEST – ONCODESIGN (ALONC – FR0011766229), a biopharmaceutical group specializing in precision medicine, is announcing the appointment of Karine Lignel as Senior Executive Vice President – Group Chief Development Officer.

“We are honored and proud to welcome Karine Lignel to our ranks. She knows our company well, as she has stood alongside and supported it with great commitment through her role as administrator, representing Crédit Mutuel Innovation since 2008,” said Philippe Genne, Founder, Chairman and Chief Executive Officer of Oncodesign“Her skills in venture capital – where she has excelled for more than 20 years in biotechnology and finance – combined with her in-depth knowledge of the company and its strategy will help us accelerate our development in a major and tangible way. We planned to accelerate external growth by acquiring companies, technologies and complementary products in line with our objectives. At the meeting point of these skills, Karine Lignel’s new role is a very strong asset for Oncodesign, and we are fully confident that she will succeed in her mission.”

Karine Lignel, new Group Chief Development Officer at Oncodesign, adds: “I am delighted to be joining Oncodesign in an operational role. I have known the company and its leaders for a very long time, and have always admired their objectives and ways of operating. In my role as shareholder representative, I witnessed the tremendous development of Oncodesign, and I am proud to now be able to work with them even more closely, bringing my own development and strategy skills. Playing a part in the discovery of new therapies, particularly for cancer, is such an important mission for me, and it means that I will be fully committed and highly motivated.”

 Karine Lignel, 53 years old, is the former President of Crédit Mutuel Innovation (€250 million of equity dedicated to investments in innovative companies), a subsidiary of Crédit Mutuel Equity. Over the course of her career, she has monitored and participated in the development of more than 60 tech companies, mainly in health, including Nanobiotix, Tissium, Maat Pharma, Endodiag, and Global Bioenergies.

Before her more than twenty-year career in venture capital that she began at Créagro, Karine Lignel had held technical and managerial positions in the industry, in particular at Barry Callebaut.

As an ENSIA (AgroParisTech) engineer, Karine Lignel holds a Master’s degree in Management and Finance from the IGIA, as well as administrator certification from the ESSEC business school.

About Oncodesign

 Oncodesign is a biopharmaceutical company dedicated to precision medicine, founded in 1995 by its current CEO and majority shareholder, and has been listed on Euronext Growth Market since April 2014. Its mission is the discovery of effective therapies to fight cancer and other diseases without therapeutic solutions. With its unique experience acquired by working with more than 1 000 clients, including the world’s largest pharmaceutical companies, along with its unique technological platform combining Artificial Intelligence, state-of-the-art medicinal chemistry, pharmacology, regulated bioanalysis, medical imaging, Oncodesign is able to select new therapeutic targets, design and develop potential preclinical candidates through to clinical phases. Oncodesign has configured its organization to offer innovative services to its customers and to license its proprietary molecules. Applied to kinase inhibitors, which represent a market estimated at over $65 billion by 2027 and accounting for almost 25% of the pharmaceutical industry’s R&D expenditure, Oncodesign’s technology has already enabled the targeting of several promising molecules with substantial therapeutic potential, in oncology and elsewhere, along with partnerships with global pharmaceutical groups. Oncodesign is based in Dijon, France, in the heart of the town’s university and hospital hub, and within the Paris-Saclay cluster. Oncodesign has 233 employees within 3 Business Units (BU): Service, Biotech, Artificial Intelligence and subsidiaries in Canada and the USA.

Contacts Press

Oncodesign |Philippe Genne | CEO
Tel. : +33 (0)380 788 260

NewCap | Investor Relations | Mathilde Bohin / Louis-Victor Delouvrier
Tel. : +33 (0)144 719 495

NewCap | Media Relations | Arthur Rouillé
Tel. : +33 (0)144 710 015

Disclaimer

This press release contains certain forward – looking statements and estimates concerning the Company’s financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words such as “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “plan,” “potential,” “predict,” “objective,” “should,” or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management’s current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the Company’s control. Consequently, the actual results, financial condition, performances and/or achievements of the Company or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and the Company undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law.

Share: